Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to ...

Think You’re Too Young for Colon Cancer? Think Again.

Figuring out who to screen could change the game. This discovery is getting us closer.
Le Lézard

Pharma is Losing $250 Billion to Patient Dropout. Here's How to Stop It.

Hoot Health today announced its entry into the pharmaceutical market with an AI-powered, physician-led patient education engine designed to address one of the industry's most costly challenges: failed ...
Le Lézard

Rare Disease Is a Mental Health Burden on Patients and Caregivers that Healthcare Professionals May Not be Meeting, Reveals Latest Global Data from Konovo

As Rare Disease Day 2026 approaches on February 28, a new Market Signals study by healthcare intelligence company Konovo, combined with data from its newly acquired Rare Patient Voice (RPV) unit, ...
University of Delaware

Aching jaw? UD scientist works to unlock mystery

UD developmental biologist studies genetics of jaw joint disorder with NIH funding ...